Document is current
Any future updates will be listed below
-
Authors
Kim, Wonkyung
Kim, Jeong Eun
Hong, Yong Sang
Hwang, Dae Wook
Kim, Jihun
Lee, Ji Sung
Shin, Jin Ho
Kim, Tae Won
Nagarkar, Deepti
Byrd, Allyson
Sung, Chang Ohk https://orcid.org/0000-0002-8567-456X
Kim, Sun Young https://orcid.org/0000-0002-5886-3920
-
Funding
Funding for this research was provided by:
This work was supported by the imCORE Network on behalf of F. Hoffmann-La Roche (ASA-1 project). (ASA-1 project)
- License Information
-
More Information
Article History
Received: 14 March 2025
Accepted: 21 May 2026
First Online: 30 May 2026
Declarations
:
: In cohort A, the study protocol was approved by the Institutional Review Board (IRB) of Asan Medical Center (approval No. 2019-0023), and surgical samples of patients who participated in our biomarker discovery program (approval No. 2011 − 0511) were used. In cohort B, the prospective study protocol was also approved by the IRB (approval No. 2018 − 1489) and registered to the clinical trial database (NCT03698461). Written informed consent was obtained from all participants for their participation in the study. All study procedures were conducted in accordance with the tenets of the Declaration of Helsinki and Good Clinical Practice.
: Not applicable.
: A.B. was a former employee of Genentech/Roche and is currently affiliated with the Center for Systems Immunology, Benaroya Research Institute, Seattle, WA, USA. D.N was a former employee of Genentech/Roche and is currently affiliated with R&D Strategic Initiatives, Genmab US Inc, Princeton, New Jersey, USA. S.Y.K reports grants from Roche/Genentech during the conduct of this study. T.W.K reports grants from Roche/Genentech, USA and Genome Insight, Inc., South Korea during the conduct of this study. The remaining authors have no competing interests.
